Login / Signup

Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666.

Mariana M S OliveiraRoberta D'AulerioTracer YongMinghui HeMarisa A P BaptistaSusanne NylénLisa S Westerberg
Published in: British journal of cancer (2023)
Our data suggest that the small molecule inhibitor CK666 is a good candidate to enhance DC cross-presentation for cancer therapy.
Keyphrases
  • dendritic cells
  • small molecule
  • cancer therapy
  • protein kinase
  • immune response
  • regulatory t cells
  • case report
  • protein protein
  • big data
  • cell therapy
  • machine learning
  • bone marrow
  • mesenchymal stem cells